A BILL

To prevent, treat, and cure tuberculosis globally.

Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

This Act may be cited as the “End Tuberculosis Now
Act of 2023”.

SEC. 2. FINDINGS.

Congress makes the following findings:

(1) Tuberculosis (referred to in the Act as “TB”) is a preventable, treatable, and curable dis-
ease, yet more than 25 years after the World Health
Organization declared it to be a public health emer-
gency and called on countries to make scaling up TB control a priority, TB remains a deadly health threat.

(2) In 2021 alone, an estimated 10,600,000 people became ill with TB, 11 percent of whom were children, and an estimated 1,600,000 of these people died from the illness. In order to achieve by 2035 the goals of the Political Declaration of the High-Level Meeting of the General Assembly on the Fight Against Tuberculosis, adopted by the United Nations General Assembly October 10, 2018, and of the World Health Organization End TB Strategy, adopted by the World Health Assembly in 2014, new and existing tools must be developed and scaled-up.

(3) More than $\frac{1}{3}$ of people who become ill with TB may be undiagnosed or misdiagnosed, resulting in unnecessary illness, communicable infections, and increased mortality.

(4) Since March 2020, the COVID–19 pandemic has severely disrupted TB responses in low- and middle-income countries, stalling and reversing years of progress made against TB. According to the World Health Organization, from 2019 to 2020—

(A) global detection of TB dropped by 18 percent;
(B) an estimated 1,300,000 fewer people were diagnosed and enrolled on TB treatment; and

(C) in some countries, TB case notifications dropped by up to 41 percent, setting progress back by up to 12 years.

(5) Failure to properly diagnose and treat TB can lead to death, can exacerbate antimicrobial resistance (a key contributor to rising cases of multi-drug-resistant TB and extensively drug-resistant TB), and can increase the probability of the introduction of resistant TB into new geographic areas.

(6) TB programs have played a central role in responding to COVID–19, including through leveraging the expertise of medical staff with expertise in TB and lung diseases, the repurposing of TB hospitals, and the use of the TB rapid molecular testing platforms and x-ray equipment for multiple purposes, including the treatment of COVID–19.

(7) With sufficient resourcing, TB program expertise, infection control, laboratory capacity, active case finding, and contact investigation can serve as platforms for respiratory pandemic response against existing and new infectious respiratory disease without disrupting ongoing TB programs and activities.
(8) Globally, only about $\frac{1}{2}$ of the $13,000,000,000 required annually, as outlined in the Stop TB Partnership’s Global Plan to End TB, is currently available.

(9) According to estimates by the Global Fund for AIDS, Tuberculosis, and Malaria, an additional $3,500,000,000 was needed during 2021 for TB programs in eligible countries in order to recover from the negative impacts of COVID–19.

(10) On September 26, 2018, the United Nations convened the first High-Level Meeting of the General Assembly on the Fight Against Tuberculosis, during which 120 countries—

(A) signed a Political Declaration to accelerate progress against TB, including through commitments to increase funding for TB prevention, diagnosis, treatment, and research and development programs, and to set ambitious goals to successfully treat 40,000,000 people with active TB and prevent at least 30,000,000 from becoming ill with TB between 2018 and 2022; and

(B) committed to “ending the epidemic in all countries, and pledge[d] to provide leadership and to work together to accelerate our na-
tional and global collective actions, investments and innovations urgently to fight this preventable and treatable disease”, as reflected in United Nations General Assembly Resolution 73/3.

(11) The United States Government continues to be a lead funder of global TB research and development, contributing 44 percent of the total $915,000,000 in global funding in 2020, and can catalyze more investments from other countries.

(12) Working with governments and partners around the world, USAID’s TB programming has saved an estimated 74,000,000 lives, demonstrating the effectiveness of United States programs and activities against the illness.

(13) On September 26, 2018, the USAID Administrator announced a new performance-based Global Accelerator to End TB, aimed at catalyzing investments to meet the treatment target set by the United Nations High-Level Meeting, further demonstrating the critical role that United States leadership and assistance plays in the fight to eliminate TB.

(14) It is essential to ensure that efforts among United States Government agencies, partner nations,
international organizations, nongovernmental organizations, the private sector, and other actors are complementary and not duplicative in order to achieve the goal of ending the TB epidemic in all countries.

SEC. 3. UNITED STATES GOVERNMENT ASSISTANCE TO COMBAT TUBERCULOSIS.

Section 104B of the Foreign Assistance Act of 1961 (22 U.S.C. 2151b–3) is amended to read as follows:

“SEC. 104B. ASSISTANCE TO COMBAT TUBERCULOSIS.

“(a) FINDINGS.—Congress makes the following findings:

“(1) The international spread of tuberculosis (referred to in this section as ‘TB’) and the deadly impact of TB’s continued existence constitutes a continuing challenge.

“(2) Additional tools and resources are required to effectively diagnose, prevent, and treat TB.

“(3) Effectively resourced TB programs can serve as a critical platform for preventing and responding to future infectious respiratory disease pandemics.

“(b) POLICY.—

“(1) IN GENERAL.—It is a major objective of the foreign assistance program of the United States
to help end the TB public health emergency through accelerated actions—

“(A) to support the diagnosis and treatment of all adults and children with all forms of TB; and

“(B) to prevent new TB infections from occurring.

“(2) SUPPORT FOR GLOBAL PLANS AND OBJECTIVES.—In countries in which the United States Government has established foreign assistance programs under this Act, particularly in countries with the highest burden of TB and other countries with high rates of infection and transmission of TB, it is the policy of the United States—

“(A) to support the objectives of the World Health Organization End TB Strategy, including its goals—

“(i) to reduce TB deaths by 95 percent by 2035;

“(ii) to reduce the TB incidence rate by 90 percent by 2035; and

“(iii) to reduce the number of families facing catastrophic health costs due to TB by 100 percent by 2035;
“(B) to support the Stop TB Partnership’s Global Plan to End TB 2023–2030, including by providing support for—

“(i) developing and using innovative new technologies and therapies to increase active case finding and rapidly diagnose and treat children and adults with all forms of TB, alleviate suffering, and ensure TB treatment completion;

“(ii) expanding diagnosis and treatment in line with the goals established by the Political Declaration of the High-Level Meeting of the General Assembly on the Fight Against Tuberculosis, including—

“(I) successfully treating 40,000,000 people with active TB by 2023, including 3,500,000 children, and 1,500,000 people with drug-resistant TB; and

“(II) diagnosing and treating latent tuberculosis infection, in support of the global goal of providing preventative therapy to at least 30,000,000 people by 2023, including 4,000,000 children younger than 5 years of age,
20,000,000 household contacts of people affected by TB, and 6,000,000 people living with HIV;

“(iii) ensuring high-quality TB care by closing gaps in care cascades, implementing continuous quality improvement at all levels of care, and providing related patient support; and

“(iv) sustainable procurements of TB commodities to avoid interruptions in supply, the procurement of commodities of unknown quality, or payment of excessive commodity costs in countries impacted by TB; and

“(C) to ensure, to the greatest extent practicable, that United States funding supports activities that simultaneously emphasize—

“(i) the development of comprehensive person-centered programs, including diagnosis, treatment, and prevention strategies to ensure that—

“(I) all people sick with TB receive quality diagnosis and treatment through active case finding; and
“(II) people at high risk for TB infection are found and treated with preventive therapies in a timely manner;

“(ii) robust TB infection control practices are implemented in all congregate settings, including hospitals and prisons;

“(iii) the deployment of diagnostic and treatment capacity—

“(I) in areas with the highest TB burdens; and

“(II) for highly at-risk and impoverished populations, including patient support services;

“(iv) program monitoring and evaluation based on critical TB indicators, including indicators relating to infection control, the numbers of patients accessing TB treatment and patient support services, and preventative therapy for those at risk, including all close contacts, and treatment outcomes for all forms of TB;

“(v) training and engagement of health care workers on the use of new diagnostic tools and therapies as they be-
come available, and increased support for training frontline health care workers to support expanded TB active case finding, contact tracing, and patient support services;

“(vi) coordination with domestic agencies and organizations to support an aggressive research agenda to develop vaccines as well as new tools to diagnose, treat, and prevent TB globally;

“(vii) linkages with the private sector on—

“(I) research and development of a vaccine, and on new tools for diagnosis and treatment of TB;

“(II) improving current tools for diagnosis and treatment of TB, including telehealth solutions for prevention and treatment; and

“(III) training healthcare professionals on use of the newest and most effective diagnostic and therapeutic tools;
“(viii) the reduction of barriers to care, including stigma and treatment and diagnosis costs, including through—

“(I) training health workers;
“(II) sensitizing policy makers;
“(III) requiring that all relevant grants and funding agreements include access and affordability provisions;
“(IV) supporting education and empowerment campaigns for TB patients regarding local TB services;
“(V) monitoring barriers to accessing TB services; and
“(VI) increasing support for patient-led and community-led TB outreach efforts;
“(ix) support for country-level, sustainable accountability mechanisms and capacity to measure progress and ensure that commitments made by governments and relevant stakeholders are met; and
“(x) support for the integration of TB diagnosis, treatment, and prevention activi-
ties into primary health care, as appropriate.

“(c) DEFINITIONS.—In this section:

“(1) APPROPRIATE CONGRESSIONAL COMMIT-TEES.—The term ‘appropriate congressional committees’ means the Committee on Foreign Relations of the Senate and the Committee on Foreign Affairs of the House of Representatives.

“(2) END TB STRATEGY.—The term ‘End TB Strategy’ means the strategy to eliminate TB that was approved by the World Health Assembly in May 2014, and is described in ‘The End TB Strategy: Global Strategy and Targets for Tuberculosis Prevention, Care and Control After 2015’.

“(3) GLOBAL ALLIANCE FOR TUBERCULOSIS DRUG DEVELOPMENT.—The term ‘Global Alliance for Tuberculosis Drug Development’ means the public-private partnership that bring together leaders in health, science, philanthropy, and private industry to devise new approaches to TB.

“(4) GLOBAL TUBERCULOSIS DRUG FACILITY.—The term ‘Global Tuberculosis Drug Facility’ means the initiative of the Stop Tuberculosis Partnership to increase access to the most advanced, affordable, quality-assured TB drugs and diagnostics.
“(5) MDR–TB.—The term ‘MDR–TB’ means multi-drug-resistant TB.

“(6) STOP TUBERCULOSIS PARTNERSHIP.—The term ‘Stop Tuberculosis Partnership’ means the partnership of 1,600 organizations (including international and technical organizations, government programs, research and funding agencies, foundations, nongovernmental organizations, civil society and community groups, and the private sector), donors, including the United States, high TB burden countries, multilateral agencies, and nongovernmental and technical agencies, which is governed by the Stop TB Partnership Coordinating Board and hosted by a United Nations entity, committed to short- and long-term measures required to control and eventually eliminate TB as a public health problem in the world.

“(7) XDR–TB.—The term ‘XDR–TB’ means extensively drug-resistant TB.

“(d) AUTHORIZATION.—To carry out this section, the President is authorized, consistent with section 104(c), to furnish assistance, on such terms and conditions as the President may determine, for the prevention, treatment, control, and elimination of TB.
“(e) GOALS.—In consultation with the appropriate congressional committees, the President shall establish goals, based on the policy and indicators described in subsection (b), for—

“(1) United States TB programs to detect, cure, and prevent all forms of TB globally for the period between 2023 and 2030 that are aligned with the End TB Strategy’s 2030 targets and the USAID’s Global Tuberculosis (TB) Strategy 2023-2030; and

“(2) updating the National Action Plan for Combating Multidrug-Resistant Tuberculosis.

“(f) COORDINATION.—

“(1) IN GENERAL.—In carrying out this section, the President shall coordinate with the World Health Organization, the Stop TB Partnership, the Global Fund to Fight AIDS, Tuberculosis, and Malaria, and other organizations with respect to the development and implementation of a comprehensive global TB response program.

“(2) BILATERAL ASSISTANCE.—In providing bilateral assistance under this section, the President, acting through the Administrator of the United States Agency for International Development, shall—
“(A) catalyze support for research and development of new tools to prevent, diagnose, treat, and control TB worldwide, particularly to reduce the incidence of, and mortality from, all forms of drug-resistant TB;

“(B) ensure United States programs and activities focus on finding individuals with active TB disease and provide quality diagnosis and treatment, including through digital health solutions, and reaching those at high risk with preventive therapy; and

“(C) ensure coordination among relevant United States Government agencies, including the Department of State, the Centers for Disease Control and Prevention, the National Institutes of Health, the Biomedical Advanced Research and Development Authority, the Food and Drug Administration, the National Science Foundation, the Department of Defense (through its Congressionally Directed Medical Research Programs), and other relevant Federal departments and agencies that engage in international TB activities—

“(i) to ensure accountability and transparency;
“(ii) to reduce duplication of efforts;
and
“(iii) to ensure appropriate integration and coordination of TB services into other United States-supported health programs.

“(g) PRIORITY TO END TB STRATEGY.—In furnishing assistance under subsection (d), the President shall prioritize—

“(1) building and strengthening TB programs—

“(A) to increase the diagnosis and treatment of everyone who is sick with TB; and

“(B) to ensure that such individuals have access to quality diagnosis and treatment;

“(2) direct, high-quality integrated services for all forms of TB, as described by the World Health Organization, which call for the coordination of active case finding, treatment of all forms of TB disease and infection, patient support, and TB prevention;

“(3) treating individuals co-infected with HIV and other co-morbidities, and other individuals with TB who may be at risk of stigma;
“(4) strengthening the capacity of health systems to detect, prevent, and treat TB, including MDR–TB and XDR–TB, as described in the latest international guidance related to TB;

“(5) researching and developing innovative diagnostics, drug therapies, and vaccines, and program-based research;

“(6) support for the Stop Tuberculosis Partnership’s Global Drug Facility, the Global Alliance for Tuberculosis Drug Development, and other organizations promoting the development of new products and drugs for TB; and

“(7) ensuring that TB programs can serve as key platforms for supporting national respiratory pandemic response against existing and new infectious respiratory disease.

“(h) ASSISTANCE FOR THE WORLD HEALTH ORGANIZATION AND THE STOP TUBERCULOSIS PARTNERSHIP.—In carrying out this section, the President, acting through the Administrator of the United States Agency for International Development, is authorized—

“(1) to provide resources to the World Health Organization and the Stop Tuberculosis Partnership to improve the capacity of countries with high burdens or rates of TB and other affected countries to
implement the End TB Strategy, the Stop TB Global Plan to End TB, their own national strategies and plans, other global efforts to control MDR–TB and XDR–TB; and

“(2) to leverage the contributions of other donors for the activities described in paragraph (1).

“(i) Annual Report on TB Activities.—Not later than December 15 of each year until the earlier of the date on which the goals specified in subsection (b)(2)(A) are met or the last day of 2030, the President shall submit an annual report to the appropriate congressional committees that describes United States foreign assistance to control TB and the impact of such efforts, including—

“(1) the number of individuals with active TB disease that were diagnosed and treated, including the rate of treatment completion and the number receiving patient support;

“(2) the number of persons with MDR–TB and XDR–TB that were diagnosed and treated, including the rate of completion, in countries receiving United States bilateral foreign assistance for TB control programs;

“(3) the number of people trained by the United States Government in TB surveillance and control;
“(4) the number of individuals with active TB disease identified as a result of engagement with the private sector and other nongovernmental partners in countries receiving United States bilateral foreign assistance for TB control programs;

“(5) a description of the collaboration and coordination of United States anti-TB efforts with the World Health Organization, the Stop TB Partnership, the Global Fund to Fight AIDS, Tuberculosis and Malaria, and other major public and private entities;

“(6) a description of the collaboration and coordination among the United States Agency for International Development and other United States departments and agencies, including the Centers for Disease Control and Prevention and the Office of the Global AIDS Coordinator, for the purposes of combating TB and, as appropriate, its integration into primary care;

“(7) the constraints on implementation of programs posed by health workforce shortages, health system limitations, barriers to digital health implementation, other challenges to successful implementation, and strategies to address such constraints;
“(8) a breakdown of expenditures for patient services supporting TB diagnosis, treatment, and prevention, including procurement of drugs and other commodities, drug management, training in diagnosis and treatment, health systems strengthening that directly impacts the provision of TB services, and research; and

“(9) for each country, and when practicable, each project site receiving bilateral United States assistance for the purpose of TB prevention, treatment, and control—

“(A) a description of progress toward the adoption and implementation of the most recent World Health Organization guidelines to improve diagnosis, treatment, and prevention of TB for adults and children, disaggregated by sex, including the proportion of health facilities that have adopted the latest World Health Organization guidelines on strengthening monitoring systems and preventative, diagnostic, and therapeutic methods, including the use of rapid diagnostic tests and orally administered TB treatment regimens;

“(B) the number of individuals screened for TB disease and the number evaluated for
TB infection using active case finding outside of health facilities;

“(C) the number of individuals with active TB disease that were diagnosed and treated, including the rate of treatment completion and the number receiving patient support;

“(D) the number of adults and children, including people with HIV and close contacts, who are evaluated for TB infection, the number of adults and children started on treatment for TB infection, and the number of adults and children completing such treatment, disaggregated by sex and, as possible, income or wealth quintile;

“(E) the establishment of effective TB infection control in all relevant congregant settings, including hospitals, clinics, and prisons;

“(F) a description of progress in implementing measures to reduce TB incidence, including actions—

“(i) to expand active case finding and contact tracing to reach vulnerable groups;
“(ii) to expand TB preventive therapy, engagement of the private sector, and diagnostic capacity;

“(G) a description of progress to expand diagnosis, prevention, and treatment for all forms of TB, including in pregnant women, children, and individuals and groups at greater risk of TB, including migrants, prisoners, miners, people exposed to silica, and people living with HIV/AIDS, disaggregated by sex;

“(H) the rate of successful completion of TB treatment for adults and children, disaggregated by sex, and the number of individuals receiving support for treatment completion;

“(I) the number of people, disaggregated by sex, receiving treatment for MDR–TB, the proportion of those treated with the latest regimens endorsed by the World Health Organization, factors impeding scale up of such treatment, and a description of progress to expand community-based MDR–TB care;

“(J) a description of TB commodity procurement challenges, including shortages,
stockouts, or failed tenders for TB drugs or other commodities;

“(K) the proportion of health facilities with specimen referral linkages to quality diagnostic networks, including established testing sites and reference labs, to ensure maximum access and referral for second line drug resistance testing, and a description of the turnaround time for test results;

“(L) the number of people trained by the United States Government to deliver high-quality TB diagnostic, preventative, monitoring, treatment, and care services;

“(M) a description of how supported activities are coordinated with—

“(i) country national TB plans and strategies; and

“(ii) TB control efforts supported by the Global Fund to Fight AIDS, Tuberculosis, and Malaria, and other international assistance programs and funds, including in the areas of program development and implementation; and

“(N) for the first 3 years of the report required under this subsection, a description of
the progress in recovering from the negative impact of COVID–19 on TB, including—

“(i) whether there has been the development and implementation of a comprehensive plan to recover TB activities from diversion of resources;

“(ii) the continued use of bidirectional TB–COVID testing; and

“(iii) progress on increased diagnosis and treatment of active TB.

“(j) ANNUAL REPORT ON TB RESEARCH AND DEVELOPMENT.—The President, acting through the Administrator of the United States Agency for International Development, and in coordination with the National Institutes of Health, the Centers for Disease Control and Prevention, the Biomedical Advanced Research and Development Authority, the Food and Drug Administration, the National Science Foundation, and the Office of the Global AIDS Coordinator, shall submit to the appropriate congressional committees until 2030 an annual report that—

“(1) describes the current progress and challenges to the development of new tools for the purpose of TB prevention, treatment, and control;

“(2) identifies critical gaps and emerging priorities for research and development, including for
rapid and point-of-care diagnostics, shortened treatments and prevention methods, telehealth solutions for prevention and treatment, and vaccines; and

“(3) describes research investments by type, funded entities, and level of investment.

“(k) EVALUATION REPORT.—Not later than 3 years after the date of the enactment of the End Tuberculosis Now Act of 2023, and 5 years thereafter, the Comptroller General of the United States shall submit a report to the appropriate congressional committees that evaluates the performance and impact on TB prevention, diagnosis, treatment, and care efforts that are supported by United States bilateral assistance funding, including recommendations for improving such programs.”.